GlassScriptPhysician profile
Christopher P Rocco
NPI 1508957952
$2,260.19
in general payments reported to CMS, 2019-2025
22 companies · $553 in 2025
The $553 reported for 2025 was more than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $250 · 2020: $162 · 2021: $337 · 2022: $386 · 2023: $277 · 2024: $296 · 2025: $553.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,126.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,126.25 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $834.19 | 2021-2025 | Duopa, Ubrelvy, Qulipta |
| Novartis Pharmaceuticals Corporation | $502.88 | 2019-2025 | |
| Allergan, INC. | $146.91 | 2020-2022 | |
| Pfizer INC. | $114.32 | 2023-2025 | |
| Acadia Pharmaceuticals INC | $77.62 | 2022 | |
| Amgen INC. | $71.05 | 2019-2022 | |
| Tanabe Pharma America, INC. | $49.39 | 2019-2022 | |
| Supernus Pharmaceuticals, INC. | $47.05 | 2019-2020 | |
| Tg Therapeutics, INC. | $45.86 | 2023-2024 | |
| Emd Serono, INC. | $41.29 | 2019 | |
| Abbott Laboratories | $40.87 | 2019-2023 | Proclaim |
| Ucb, INC. | $39.69 | 2022 | |
| Biogen, INC. | $38.87 | 2021 | |
| Jazz Pharmaceuticals INC. | $33.60 | 2025 | |
| Globus Medical, INC. | $33.56 | 2025 | Senza |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $31.40 | 2022 | |
| Teva Pharmaceuticals USA, INC. | $28.31 | 2019 | |
| Sumitomo Pharma America, INC. | $24.24 | 2023 | Aptiom |
| Celgene Corporation | $15.97 | 2022 | |
| Argenx US, INC. | $15.57 | 2023 | Vyvgart |
| Eisai INC. | $15.53 | 2021 | |
| Sunovion Pharmaceuticals INC. | $12.02 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Christopher Rocco listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.